Astellas Pharma Inc. - Product Pipeline Review - 2016

Date: May 31, 2016
Pages: 285
Price:
US$ 1,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A5D6940CB87EN
Leaflet:

Download PDF Leaflet

Astellas Pharma Inc. - Product Pipeline Review - 2016

SUMMARY

Global Markets Direct’s, ‘Astellas Pharma Inc. - Product Pipeline Review - 2016’, provides an overview of the Astellas Pharma Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Astellas Pharma Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the pipeline therapeutic landscape of Astellas Pharma Inc.
  • The report provides overview of Astellas Pharma Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Astellas Pharma Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Astellas Pharma Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
REASONS TO BUY
  • Evaluate Astellas Pharma Inc.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Astellas Pharma Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Astellas Pharma Inc.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Astellas Pharma Inc. Snapshot
Astellas Pharma Inc. Overview
Key Information
Key Facts
Astellas Pharma Inc. - Research and Development Overview
Key Therapeutic Areas
Astellas Pharma Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Astellas Pharma Inc. - Pipeline Products Glance
Astellas Pharma Inc. - Late Stage Pipeline Products
Astellas Pharma Inc. - Clinical Stage Pipeline Products
Astellas Pharma Inc. - Early Stage Pipeline Products
Astellas Pharma Inc. - Drug Profiles
linaclotide
solifenacin succinate
tacrolimus ER
(ipragliflozin + sitagliptin phosphate)
(mirabegron + solifenacin succinate)
amenamevir
ASP-0113
bendamustine hydrochloride
degarelix acetate
enzalutamide
evolocumab
fidaxomicin
gilteritinib fumarate
mirabegron ER
naquotinib mesylate
peficitinib hydrobromide
quetiapine fumarate ER
romosozumab
roxadustat
AGS-16C3F
ASP-1707
ASP-3662
ASP-7962
ASP-8232
erlotinib hydrochloride
FG-2216
ipragliflozin
linsitinib
MA09-hRPE
regadenoson
blinatumomab
AGS-67E
ASG-15ME
ASP-0819
ASP-2205
ASP-2905
ASP-4132
ASP-4345
ASP-5094
ASP-5878
ASP-6282
ASP-6294
ASP-7266
ASP-7398
ASP-8062
enfortumab vedotin
OSI-930
AS-1069562
AS-1669058
AS-1940477
AS-2034178
AS-2077715
AS-2444697
AS-2521780
AS-2575959
AS-2715348
AS-2795440
AS-288640100
ASP-1017
ASP-1645
ASP-3258
ASP-5736
ASP-6537
ASP-7663
ASP-9133
ASP-9726
FK-886
Gene Therapy to Activate mVChR1 for Retinits Pigmentosa
KB-425796C
Monoclonal Antibody Conjugates for Oncology
OSI-296
Small Molecule 2 for Epilepsy
Small Molecule 3 for Epilepsy
Small Molecule 4 for Epilepsy
Small Molecule for Epilepsy
Small Molecule to Block N-type Calcium and hERG Potassium Channels for Neuropathic Pain
Small Molecule to Inhibit 17-Beta-HSD for Castration-Resistant Prostate Cancer
Small Molecule to Inhibit JAK3 for Heart Transplantation
Small Molecule to Inhibit PDE10A for Schizophrenia
Small Molecule to Inhibit TAK1 for Ovarian Cancer
Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine
Small Molecules to Inhibit DAAO for Cognitive Disorders
Small Molecules to Inhibit RANKL for Osteoclastogenesis
Stem Cell Therapy for Autoimmune Diseases
Stem Cell Therapy for Corneal Blindness
Stem Cell Therapy for Glaucoma
Stem Cell Therapy for Ophthalmic Disorders
UMN-0901
AS-1468240
Drugs for Pancreatic Cancer
KB-425796A
Monoclonal Antibodies for Oncology
Small Molecules for Non-Neuromuscular and Neuromuscular Disorders
Small Molecules to Activate Troponin for Non-Neuromuscular and Neuromuscular Disorders
Small Molecules to Inhibit ACK1 for Oncology
Astellas Pharma Inc. - Pipeline Analysis
Astellas Pharma Inc. - Pipeline Products by Target
Astellas Pharma Inc. - Pipeline Products by Route of Administration
Astellas Pharma Inc. - Pipeline Products by Molecule Type
Astellas Pharma Inc. - Pipeline Products by Mechanism of Action
Astellas Pharma Inc. - Recent Pipeline Updates
Astellas Pharma Inc. - Dormant Projects
Astellas Pharma Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Astellas Pharma Inc. - Company Statement
Astellas Pharma Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Astellas Pharma Inc. - Key Manufacturing Facilities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Astellas Pharma Inc., Key Information
Astellas Pharma Inc., Key Facts
Astellas Pharma Inc. - Pipeline by Indication, 2016
Astellas Pharma Inc. - Pipeline by Stage of Development, 2016
Astellas Pharma Inc. - Monotherapy Products in Pipeline, 2016
Astellas Pharma Inc. - Combination Treatment Modalities in Pipeline, 2016
Astellas Pharma Inc. - Partnered Products in Pipeline, 2016
Astellas Pharma Inc. - Partnered Products/ Combination Treatment Modalities, 2016
Astellas Pharma Inc. - Out-Licensed Products in Pipeline, 2016
Astellas Pharma Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
Astellas Pharma Inc. - Pre-Registration, 2016
Astellas Pharma Inc. - Filing rejected/Withdrawn, 2016
Astellas Pharma Inc. - Phase III, 2016
Astellas Pharma Inc. - Phase II, 2016
Astellas Pharma Inc. - Phase I, 2016
Astellas Pharma Inc. - IND/CTA Filed, 2016
Astellas Pharma Inc. - Preclinical, 2016
Astellas Pharma Inc. - Discovery, 2016
Astellas Pharma Inc. - Pipeline by Target, 2016
Astellas Pharma Inc. - Pipeline by Route of Administration, 2016
Astellas Pharma Inc. - Pipeline by Molecule Type, 2016
Astellas Pharma Inc. - Pipeline Products by Mechanism of Action, 2016
Astellas Pharma Inc. - Recent Pipeline Updates, 2016
Astellas Pharma Inc. - Dormant Developmental Projects,2016
Astellas Pharma Inc. - Discontinued Pipeline Products, 2016
Astellas Pharma Inc., Other Locations
Astellas Pharma Inc., Subsidiaries
Astellas Pharma Inc., Key Manufacturing Facilities

LIST OF FIGURES

Astellas Pharma Inc. - Pipeline by Top 10 Indication, 2016
Astellas Pharma Inc. - Pipeline by Stage of Development, 2016
Astellas Pharma Inc. - Monotherapy Products in Pipeline, 2016
Astellas Pharma Inc. - Partnered Products in Pipeline, 2016
Astellas Pharma Inc. - Out-Licensed Products in Pipeline, 2016
Astellas Pharma Inc. - Pipeline by Top 10 Target, 2016
Astellas Pharma Inc. - Pipeline by Route of Administration, 2016
Astellas Pharma Inc. - Pipeline by Molecule Type, 2016
Astellas Pharma Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Skip to top


Koronis Pharma, Inc. - Product Pipeline Review - 2014 US$ 1,125.00 Aug, 2014 · 24 pages
Kite Pharma, Inc. - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 44 pages
aTyr Pharma, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Jun, 2015 · 22 pages
Cerulean Pharma, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 29 pages
Gemmus Pharma Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Apr, 2015 · 21 pages

Ask Your Question

Astellas Pharma Inc. - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: